About Medivation
Medivation is a Healthcare company based in San Francisco (United States) founded in 2004, and was acquired by Pfizer in August 2016. Early-stage cancer therapeutics are acquired, developed, and partnered. The company has 667 employees. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
Medivation acquires early-development stage pharmaceuticals, develop those product candidates, and then partner or sell successful programs to larger companies. Their pipeline includes enzalutamide, an androgen receptor inhibitor approved for the metastatic castration-resistant prostate cancer (CRPC), and being further developed for earlier stages of prostate cancer, advanced breast cancer and hepatocellular carcinoma (Phase 3); Talazoparib (MDV3800), an orally available poly-ADP ribose polymerase, or PARP, inhibitor currently is in Phase 3 clinical trial for gBRCA mutated breast cancer (i.e., advanced breast cancer in patients whose BRCA genes contain germline mutations). They are targeting number of other solid tumor indications in including breast (beyond gBRCA mutations), prostate, small cell lung, and ovarian cancers and Pidilizumab (MDV9300), an antibody with immune-mediated anti-tumor effects, licensed from CureTechin 2014, in development for diffuse large B-cell lymphoma and other hematologic malignancies, such as multiple myeloma.
- Headquarters San Francisco, United States
- Employees 667
- Stage Acquired
- SectorsHealthcare
- Website medivation.com
- Social LinkedIn X
- Acquired by Pfizer (Aug 2016)
Funding Insights of Medivation
- Total Rounds 4
- Last Round Debt – Conventional — $100M
- First Round $12.97M
(Jun 2005)
All 4 funding rounds of Medivation with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2007 | $100M | Debt – Conventional | – | – | – |
| Dec 2006 | $33.6M | Post-IPO | – | – | – |
| May 2006 | $13.25M | Post-IPO | – | – | – |
| Jun 2005 | $12.97M | Post-IPO | – | – | – |
1 investors in total: 1 institutional.
Investors in Medivation
Medivation has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Pfizer.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Pharmaceutical products for treating multiple diseases are provided. | 1849 | pfizer.com | New York, United States |
Investor details for Medivation
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Medivation
4 dated milestones of Medivation across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Medivation is founded.
- Funding First funding round of $13.0M.
- Funding Latest funding round, Debt – Conventional, of $100.0M.
- Exit Acquired by Pfizer.
Competitors of Medivation
Medivation has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of Medivation
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Medivation
Websites that share an audience with Medivation (medivation.com).
Websites whose visitors overlap most with Medivation. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| exelixis.com | 100% | 39.1K | #1,001,350 | View details | |
| merck.com | 94% | 656.8K | #78,842 | View details | |
| seattlegenetics.com | 91% | View details | |||
| pharmacyclics.com | 83% | 3.1K | #5,482,945 | View details | |
| genoptix.com | 82% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 26 similar websites and full traffic analytics for Medivation
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 26 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as Medivation (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Medivation
Complete news archive for Medivation
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Medivation
Medivation was founded in 2004 and raised its 1st funding round 1 year after it was founded.
Medivation is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Medivation has 667 employees.
Medivation acquires early-development stage pharmaceuticals, develop those product candidates, and then partner or sell successful programs to larger companies. Their pipeline includes enzalutamide, an androgen receptor inhibitor approved for the metastatic castration-resistant prostate cancer (CRPC), and being further developed for earlier stages of prostate cancer, advanced breast cancer and hepatocellular carcinoma (Phase 3); Talazoparib (MDV3800), an orally available poly-ADP ribose polymerase, or PARP, inhibitor currently is in Phase 3 clinical trial for gBRCA mutated breast cancer (i.e., advanced breast cancer in patients whose BRCA genes contain germline mutations). They are targeting number of other solid tumor indications in including breast (beyond gBRCA mutations), prostate, small cell lung, and ovarian cancers and Pidilizumab (MDV9300), an antibody with immune-mediated anti-tumor effects, licensed from CureTechin 2014, in development for diffuse large B-cell lymphoma and other hematologic malignancies, such as multiple myeloma.
Medivation has 1 investor. Key investors include Pfizer.
Yes. Medivation was acquired by Pfizer in August 2016.